Pharma Major Shares Rebound from Lows; Firm Reports 39.5 per cent Profit Growth

The company reported a net income of Rs 8,552 crore, marking a 39.5 per cent YoY growth. Total sales increased 10.6 per cent YoY to Rs 56,186 crore from Rs 50,799 crore in Q3 FY24

Lupin Limited delivered a robust financial performance in Q3 FY25, driven by strong revenue growth, improved margins, and key strategic developments across markets.

Consolidated Financial Performance

• Sales: Total sales increased 10.6 per cent YoY to Rs 56,186 crore from Rs 50,799 crore in Q3 FY24. On a quarter-over-quarter (QoQ) basis, sales grew by 2.2 per cent.
• Net Income: The company posted a net income of Rs 8,552 crore, reflecting a 39.5 per cent YoY growth and a 0.3 per cent sequential increase.
• Gross Profit: Excluding other operating income, gross profit rose 16.2 per cent YoY to Rs 38,970 crore.
• Other Operating Income: At Rs 1,492 crore, other operating income increased by 27 per cent YoY but declined 15.1 per cent QoQ.
• R&D Expenses: Lupin invested Rs 4,344 crore in R&D, accounting for 7.7 per cent of sales, up from 7 per cent in Q3 FY24.
• Capital Expenditure: Capex stood at Rs 1,241 crore, representing 2.2 per cent of total sales.

Key Highlights of Q3 FY25

Margin Improvement:

The company recorded a steady improvement in operating margins, supported by higher efficiency.

Geographic Sales Growth:

• India: Sales grew 12 per cent YoY to Rs 19,305 crore, outperforming market growth.
• North America: Sales declined 5 per cent YoY to Rs 21,213 crore.
• Emerging Markets: Revenue surged 21 per cent YoY to Rs 4,508 crore.
• EMEA: Sales rose 2 per cent YoY to Rs 6,249 crore.
• API Business: API segment revenue increased 12 per cent YoY to Rs 2,891 crore.

Key Approvals & Launches:

• Launched generic Pred Forte with 180-day CGT exclusivity.
• Received US FDA approval for Emtricitabine & Tenofovir Alafenamide Tablets.
• Achieved regulatory approvals for Pune Biotech and Pithampur Unit-I facilities.

Business Developments:

• Acquired Eli Lilly’s Huminsulin to strengthen its India diabetes portfolio.
• Partnered for NaMuscla commercialization in Argentina and Colombia.
• Filed Ranibizumab for the EU market.

Lupin shares declined by 3 per cent during intraday trading on February 12, touching a low of Rs 1,999.45, before recovering slightly to close 2.05 per cent lower at Rs 2,025.25. Despite the decline, the stock has gained 27.02 per cent over the past year.

Lupin Limited is a global pharmaceutical company engaged in the development, production, and marketing of branded and generic medicines, biotechnology products, and active pharmaceutical ingredients (APIs). The company specializes in various therapeutic segments, including Cardiovascular, Diabetology, Asthma, Pediatrics, CNS, GI, Anti-infectives, and NSAIDs. Additionally, it holds a leadership position in the Anti-TB and Cephalosporins sectors. With manufacturing units in India, the USA, Mexico, and Brazil, Lupin serves global markets.

Disclaimer: This article is for informational purposes only and does not constitute investment advice.